Swiss pharmaceutical company evaluates Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
A family-owned pharmaceutical company Octapharma is conducting the clinical trial Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection.
It is planned to include 300 participants.
Actual study start date is October 19, 2020. The researchers expect to complete the study by January 2021.
A target of 150 patients (male and female) hospitalised with severe COVID-19 infection and having required oxygen therapy (including those requiring a ventilator, central venous catheter or ECMO) will be included into this study. A control group of matched numbers of non-COVID-19 patients hospitalised and having required oxygen therapy will be included.
One primary outcome measure is Antithrombin Levels, Levels of AT in severely ill COVID-19 positive patients receiving/not receiving ATIII treatment.
Among the exclusion criteria are:
- Known hypersensitivity or allergic reaction to ATIII
- Participation in any interventional trial during the time of individual observational period (date of hospitalisation to the date of removal of oxygen therapy or death, whichever occurred first)
- Pregnant women
The location of the study is as follows (further details can be found here https://ichgcp.net/clinical-trials-registry/NCT04651400) Innsbruck, Austria; Wien, Austria; Strasbourg, France; Aachen, Germany; Essen, Germany.
